Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/fb694c05-9d9d-4bb4-a412-86d9b0bc952d/

ANIP

ANI Pharmaceuticals Inc
Chart
77.65 USD
Latest Week 2026-07-24
HealthcareDrug Manufacturers - Specialty & GenericSMALL
Snapshot 2026-07-26 · 0.6w · Fresh
0.91
OS Score
73.0%
Value
96.0%
Quality
68.0%
Momentum
6/9
F-Score
0.837
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
7 of 23 passing
★
OS Composite
OS 0.910
↗
Trending Value
✗
◆
Quality × Value
QV 0.837
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
13.2%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
Rev +37%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 25%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
Val 73%
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.96
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
73.0%ile
P/E
19.7×
P/S
1.9×
P/B
3.1×
E/P
0.0815
FCF Yield
0.144
EBITDA/EV
0.132
SH Yield
0.007
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
28.00000000
/100 — 1=cheapest
VC2 (Trending Value)
32.00000000
/100
VC3 (Buyback)
33.00000000
/100
FCF yield of 14.4% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
96.0%ile
ROE
0.159
ROA
0.063
Net Margin
0.097
Op Margin
0.157
GPA
0.428
D/E
1.53
Current
3.12
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.370
Stability
2.261
lower=better
Accruals
-0.084
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
68.0%ile
6M Return
-6.4%
12M Return
15.1%
12-1 Mom
25.2%
Risk-Adj
0.62
Vol 252d
40.5%
Vol 60d
67.4%
↑ Expanding
Max DD 12M
-27.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 25% is very strong — a clear uptrend. Near-term vol (67%) is expanding vs long-term (40%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.91
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
85.0%
Sector Quality %ile
96.0%
P/E z-score
-0.12
P/B z-score
-0.16
Sector Avg OS
64.8%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
MD Mednax Inc 97.0% 86.0% 84.0% 94.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (73th) and quality (96th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Growth at Reasonable Price
Revenue growing 37% with P/E of 20×. Growth isn't fully priced in.
Volatility Expanding
60-day vol (67%) significantly exceeds 252-day (40%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
65.8% avg (7 factors)
Quality
B
65.8% avg (8 factors)
Momentum
C
46.8% avg (4 factors)
Risk
C
49.2% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.910—8—
Value %ile0.730—2—
Quality %ile0.960—8—
Momentum %ile0.680—0—
F-Score6.000—0—
Confidence0.929—8—
Volatility0.405—5—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
19.69
Earnings Yield (E/P)
0.0815
Price / Sales
1.91
Price / Book
3.14
Price / Cash Flow
8.46
FCF Yield
14.4%
EBITDA / EV
13.2%
Sales Yield (1/P·S)
0.5184
Shareholder Yield
Div + net buyback / mktcap
0.7%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
15.9%
Return on Assets
6.3%
Net Margin
9.7%
Operating Margin
15.7%
Gross Profit / Assets
Novy-Marx GPA
42.8%
Debt / Equity
1.53
Current Ratio
3.12
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.084
External Financing
Net issuance — lower=better
0.009
MomentumPrice trend strength over different horizons
6M Return
-6.4%
12M Return
15.1%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
25.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.62
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
37.0%
Earnings Stability (CV)
Lower = more stable
2.261
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Dividend Yield
0.0%
Buyback Yield
0.7%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
28
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
32
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
33
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity